<DOC>
	<DOCNO>NCT02216409</DOCNO>
	<brief_summary>The purpose study assess safety tolerability Hu5F9-G4 participant solid tumor .</brief_summary>
	<brief_title>Phase 1 Trial Hu5F9-G4 , CD47-targeting Antibody</brief_title>
	<detailed_description>This first-in-human , first-in-class , escalate dose trial antibody inhibit anti-apoptotic signal human macrophage . The major aim study define safety profile new drug , determine recommend dose schedule potential additional trial .</detailed_description>
	<criteria>Patients histologically cytologically confirm advanced solid malignancy Lymphoma Relapsed refractory disease least 1 prior systemic treatment primary malignancy candidate curative treatment . Adequate hematologic status Adequate coagulation function Adequate hepatic function Adequate renal function Known primary tumor central nervous system disease Known active brain metastasis Known cardiopulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>